RU2018135072A3 - - Google Patents

Info

Publication number: RU2018135072A3
Authority: RU; Russia

Application number

RU2018135072A

Other versions

RU2018135072A (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-08

Filing date

2017-03-07

Publication date

2020-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58387911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018135072(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-03-07 Application filed filed Critical

2020-04-08 Publication of RU2018135072A publication Critical patent/RU2018135072A/ru

2020-10-15 Publication of RU2018135072A3 publication Critical patent/RU2018135072A3/ru

2021-09-28 Application granted granted Critical

2021-09-28 Publication of RU2756223C2 publication Critical patent/RU2756223C2/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

RU2018135072A 2016-03-08 2017-03-07 Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения RU2756223C2 (ru)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201662305393P	2016-03-08	2016-03-08
US62/305,393		2016-03-08
US201662346336P	2016-06-06	2016-06-06
US62/346,336		2016-06-06
PCT/US2017/021172 WO2017156009A1 (en)	2016-03-08	2017-03-07	Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

Publications (3)

Publication Number	Publication Date
RU2018135072A RU2018135072A (ru)	2020-04-08
RU2018135072A3 true RU2018135072A3 (ru)	2020-10-15
RU2756223C2 RU2756223C2 (ru)	2021-09-28

Family

ID=58387911

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2018135072A RU2756223C2 (ru)	2016-03-08	2017-03-07	Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения

Country Status (30)

Country	Link
US (6)	US10100021B2 (ru)
EP (1)	EP3408260B1 (ru)
JP (2)	JP7306828B2 (ru)
KR (2)	KR20180114225A (ru)
CN (1)	CN108779084A (ru)
AU (1)	AU2017229466C1 (ru)
CA (1)	CA3015505C (ru)
CL (1)	CL2018002539A1 (ru)
CO (1)	CO2018010568A2 (ru)
CY (1)	CY1124397T1 (ru)
DK (1)	DK3408260T3 (ru)
ES (1)	ES2880123T3 (ru)
HR (1)	HRP20211169T1 (ru)
HU (1)	HUE055546T2 (ru)
IL (1)	IL261244B (ru)
LT (1)	LT3408260T (ru)
MX (1)	MX377177B (ru)
MY (1)	MY198185A (ru)
PH (1)	PH12018501876A1 (ru)
PL (1)	PL3408260T3 (ru)
PT (1)	PT3408260T (ru)
RS (1)	RS62172B1 (ru)
RU (1)	RU2756223C2 (ru)
SA (1)	SA518392325B1 (ru)
SG (1)	SG11201807591VA (ru)
SI (1)	SI3408260T1 (ru)
SM (1)	SMT202100434T1 (ru)
TW (1)	TWI731943B (ru)
WO (1)	WO2017156009A1 (ru)
ZA (1)	ZA201805840B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS62172B1 (sr)	2016-03-08	2021-08-31	Theravance Biopharma R&D Ip Llc	Kristalna (2s,4r)-5-(5’-hloro-2-fluoro-[1,1’-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi izoksazol-5-karboksamido)-2-metilpentanska kiselina i njene upotrebe
CN113286585B (zh) *	2019-09-20	2022-11-08	深圳信立泰药业股份有限公司	血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
KR102485499B1 (ko) *	2022-07-15	2023-01-09	오가노이드사이언스 주식회사	신장 질환의 치료 또는 예방용 조성물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4189604A (en)	1975-07-22	1980-02-19	Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai	Bestatin
US4206232A (en)	1976-05-10	1980-06-03	E. R. Squibb & Sons, Inc.	Relieving hypertension with carboxyalkylacylamino acids
IL58849A (en)	1978-12-11	1983-03-31	Merck & Co Inc	Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
FR2480747A1 (fr)	1980-04-17	1981-10-23	Roques Bernard	Derives d'acides amines et leur application therapeutique
US4906615A (en)	1980-12-18	1990-03-06	Schering Corporation	Substituted dipeptides as inhibitors of enkephalinases
US4722810A (en)	1984-08-16	1988-02-02	E. R. Squibb & Sons, Inc.	Enkephalinase inhibitors
US4939261A (en)	1984-06-08	1990-07-03	Ciba-Geigy Corporation	N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase
EP0225292A3 (en)	1985-12-06	1988-11-30	Ciba-Geigy Ag	Certain n-substituted butyramide derivatives
US4929641B1 (en)	1988-05-11	1994-08-30	Schering Corp	Mercapto-acylamino acid antihypertensives
KR880007441A (ko)	1986-12-11	1988-08-27	알렌 제이.스피겔	스피로-치환된 글루타르아미드 이뇨제
FR2623498B1 (fr)	1987-11-24	1990-04-06	Bioprojet Soc Civ	Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques
GB8820844D0 (en)	1988-09-05	1988-10-05	Pfizer Ltd	Therapeutic agents
US5599951A (en)	1989-09-15	1997-02-04	Societe Civile Bioprojet	Amino acid derivatives, the process for their preparation and their applications to therapy
US5294632A (en)	1991-05-01	1994-03-15	Ciba-Geigy Corporation	Phosphono/biaryl substituted dipetide derivatives
US5155100A (en)	1991-05-01	1992-10-13	Ciba-Geigy Corporation	Phosphono/biaryl substituted dipeptide derivatives
US5217996A (en)	1992-01-22	1993-06-08	Ciba-Geigy Corporation	Biaryl substituted 4-amino-butyric acid amides
US5508272A (en)	1993-06-15	1996-04-16	Bristol-Myers Squibb Company	Compounds containing a fused bicycle ring and processes therefor
DE19510566A1 (de)	1995-03-23	1996-09-26	Kali Chemie Pharma Gmbh	Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CA2218716A1 (en)	1995-04-21	1996-10-24	Novartis Ag	N-aroylamino acid amides as endothelin inhibitors
US6660756B2 (en)	2001-03-28	2003-12-09	Pfizer Inc.	N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
GB0119305D0 (en)	2001-04-12	2001-10-03	Aventis Pharma Gmbh	Mercaptoacetylamide derivatives,a process for their preparation and their use
WO2006027680A1 (en)	2004-09-10	2006-03-16	Pfizer Limited	3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CA2637588A1 (en)	2006-02-17	2007-08-30	Monsanto Technology Llc	Chimeric regulatory sequences comprising introns from dicotyledons for plant gene expression
WO2007106708A2 (en)	2006-03-10	2007-09-20	Novartis Ag	Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI413638B (zh)	2007-01-12	2013-11-01	Novartis Ag	新穎方法
TWI448284B (zh)	2007-04-24	2014-08-11	Theravance Inc	雙效抗高血壓劑
PE20091364A1 (es)	2008-01-17	2009-10-13	Novartis Ag	Proceso para la preparacion de inhibidores de nep
ES2523734T3 (es)	2009-05-28	2014-12-01	Novartis Ag	Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
JP5466759B2 (ja) *	2009-05-28	2014-04-09	ノバルティスアーゲー	ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN102712585B (zh)	2010-01-22	2015-06-24	诺华股份有限公司	中性内肽酶抑制剂中间体和其制备方法
US8993631B2 (en)	2010-11-16	2015-03-31	Novartis Ag	Method of treating contrast-induced nephropathy
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
ME02295B (me)	2010-12-15	2016-02-20	Theravance Biopharma R&D Ip Llc	Inhibitori neprilizina
CN103261168B (zh)	2010-12-15	2015-08-05	施万生物制药研发Ip有限责任公司	脑啡肽酶抑制剂
WO2012154249A1 (en)	2011-02-17	2012-11-15	Theravance, Inc.	Substituted aminobutyric derivatives as neprilysin inhibitors
SG192815A1 (en) *	2011-02-17	2013-09-30	Theravance Inc	Substituted aminobutyric derivatives as neprilysin inhibitors
JP5959075B2 (ja)	2011-05-31	2016-08-02	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	ネプリライシン阻害剤
WO2012166389A1 (en)	2011-05-31	2012-12-06	Theravance, Inc.	Neprilysin inhibitors
EP2714662B1 (en)	2011-05-31	2017-10-11	Theravance Biopharma R&D IP, LLC	Neprilysin inhibitors
TWI560172B (en)	2011-11-02	2016-12-01	Theravance Biopharma R&D Ip Llc	Neprilysin inhibitors
CN104350052B (zh)	2012-05-31	2017-05-31	施万生物制药研发Ip有限责任公司	一氧化氮供体脑啡肽酶抑制剂
SG11201408094YA (en)	2012-06-08	2015-01-29	Theravance Biopharma R & D Ip Llc	Neprilysin inhibitors
US8871792B2 (en)	2012-06-08	2014-10-28	Theravance Biopharma R&D Ip, Llc	Neprilysin inhibitors
HUE031301T2 (hu)	2012-08-08	2017-07-28	Theravance Biopharma R&D Ip Llc	Neprilizin inhibitorok
KR101811549B1 (ko) *	2013-06-19	2017-12-26	에프. 호프만-라 로슈 아게	인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체
WO2015116786A1 (en) *	2014-01-30	2015-08-06	Theravance Biopharma R&D Ip, Llc	Neprilysin inhibitors
RS62172B1 (sr)	2016-03-08	2021-08-31	Theravance Biopharma R&D Ip Llc	Kristalna (2s,4r)-5-(5’-hloro-2-fluoro-[1,1’-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi izoksazol-5-karboksamido)-2-metilpentanska kiselina i njene upotrebe

2017
- 2017-03-07 RS RS20210963A patent/RS62172B1/sr unknown
- 2017-03-07 KR KR1020187028757A patent/KR20180114225A/ko not_active Ceased
- 2017-03-07 WO PCT/US2017/021172 patent/WO2017156009A1/en not_active Ceased
- 2017-03-07 CA CA3015505A patent/CA3015505C/en active Active
- 2017-03-07 AU AU2017229466A patent/AU2017229466C1/en active Active
- 2017-03-07 SG SG11201807591VA patent/SG11201807591VA/en unknown
- 2017-03-07 JP JP2018546864A patent/JP7306828B2/ja active Active
- 2017-03-07 HR HRP20211169TT patent/HRP20211169T1/hr unknown
- 2017-03-07 DK DK17712605.9T patent/DK3408260T3/da active
- 2017-03-07 US US15/452,333 patent/US10100021B2/en active Active
- 2017-03-07 SI SI201730845T patent/SI3408260T1/sl unknown
- 2017-03-07 LT LTEP17712605.9T patent/LT3408260T/lt unknown
- 2017-03-07 PL PL17712605T patent/PL3408260T3/pl unknown
- 2017-03-07 HU HUE17712605A patent/HUE055546T2/hu unknown
- 2017-03-07 CN CN201780016076.5A patent/CN108779084A/zh active Pending
- 2017-03-07 MY MYPI2018702868A patent/MY198185A/en unknown
- 2017-03-07 ES ES17712605T patent/ES2880123T3/es active Active
- 2017-03-07 SM SM20210434T patent/SMT202100434T1/it unknown
- 2017-03-07 RU RU2018135072A patent/RU2756223C2/ru active
- 2017-03-07 KR KR1020227008251A patent/KR20220035991A/ko not_active Ceased
- 2017-03-07 EP EP17712605.9A patent/EP3408260B1/en active Active
- 2017-03-07 PT PT177126059T patent/PT3408260T/pt unknown
- 2017-03-07 MX MX2018010727A patent/MX377177B/es active IP Right Grant
- 2017-03-07 TW TW106107450A patent/TWI731943B/zh active
2018
- 2018-08-20 IL IL261244A patent/IL261244B/en unknown
- 2018-08-30 ZA ZA2018/05840A patent/ZA201805840B/en unknown
- 2018-09-02 SA SA518392325A patent/SA518392325B1/ar unknown
- 2018-09-03 PH PH12018501876A patent/PH12018501876A1/en unknown
- 2018-09-05 CL CL2018002539A patent/CL2018002539A1/es unknown
- 2018-09-10 US US16/125,991 patent/US10472335B2/en active Active
- 2018-10-02 CO CONC2018/0010568A patent/CO2018010568A2/es unknown
2019
- 2019-09-25 US US16/582,051 patent/US10752599B2/en active Active
2020
- 2020-07-14 US US16/928,206 patent/US11230536B2/en active Active
2021
- 2021-07-30 CY CY20211100685T patent/CY1124397T1/el unknown
- 2021-10-29 JP JP2021177448A patent/JP2022017433A/ja active Pending
- 2021-12-14 US US17/550,564 patent/US11718591B2/en active Active
2024
- 2024-02-15 US US18/442,885 patent/US12351561B2/en active Active

Also Published As

Publication number	Publication date
IL261244B (en)	2022-02-01
BR112018068170A2 (pt)	2019-01-29
RU2018135072A (ru)	2020-04-08
US20170275259A1 (en)	2017-09-28
MX377177B (es)	2025-03-07
RU2756223C2 (ru)	2021-09-28
JP2019509286A (ja)	2019-04-04
HUE055546T2 (hu)	2021-12-28
ZA201805840B (en)	2019-07-31
PT3408260T (pt)	2021-07-23
AU2017229466A1 (en)	2018-09-13
SA518392325B1 (ar)	2022-08-03
SG11201807591VA (en)	2018-10-30
KR20180114225A (ko)	2018-10-17
US20210061776A1 (en)	2021-03-04
CA3015505C (en)	2024-03-05
US10472335B2 (en)	2019-11-12
PH12018501876A1 (en)	2019-01-28
US20220242836A1 (en)	2022-08-04
CO2018010568A2 (es)	2018-10-22
JP2022017433A (ja)	2022-01-25
CL2018002539A1 (es)	2018-10-26
DK3408260T3 (da)	2021-08-02
ES2880123T3 (es)	2021-11-23
WO2017156009A1 (en)	2017-09-14
US20190002416A1 (en)	2019-01-03
SMT202100434T1 (it)	2021-09-14
US20240327360A1 (en)	2024-10-03
US11718591B2 (en)	2023-08-08
PL3408260T3 (pl)	2021-11-08
MX2018010727A (es)	2019-01-24
CN108779084A (zh)	2018-11-09
EP3408260B1 (en)	2021-05-05
IL261244A (en)	2018-10-31
LT3408260T (lt)	2021-07-26
TW201741290A (zh)	2017-12-01
RS62172B1 (sr)	2021-08-31
AU2017229466B2 (en)	2020-08-13
CA3015505A1 (en)	2017-09-14
SI3408260T1 (sl)	2021-08-31
EP3408260A1 (en)	2018-12-05
KR20220035991A (ko)	2022-03-22
TWI731943B (zh)	2021-07-01
US10752599B2 (en)	2020-08-25
US20200157061A1 (en)	2020-05-21
AU2017229466C1 (en)	2021-02-11
US11230536B2 (en)	2022-01-25
HRP20211169T1 (hr)	2021-11-12
MY198185A (en)	2023-08-09
US12351561B2 (en)	2025-07-08
CY1124397T1 (el)	2022-07-22
US10100021B2 (en)	2018-10-16
JP7306828B2 (ja)	2023-07-11

Publication	Publication Date	Title
BR112019009389A2 (ru)	2019-07-23
BR122021013712A2 (ru)	2019-11-19
BR122020022459A2 (ru)	2019-06-25
BR112019009192A2 (ru)	2019-07-23
BR112019006736A2 (ru)	2019-07-23
BR202016025584U2 (ru)	2018-05-29
BR202016021516U2 (ru)	2018-04-03
CN303536208S (ru)	2016-01-06
CN303536549S (ru)	2016-01-06
CN303536232S (ru)	2016-01-06
CN303681103S (ru)	2016-05-25
CN303661473S (ru)	2016-05-04
CN303537800S (ru)	2016-01-06
CN303536129S (ru)	2016-01-06
CN303535547S (ru)	2016-01-06
CN303660730S (ru)	2016-05-04
CN303649158S (ru)	2016-04-20
CN303688583S (ru)	2016-06-01
CN303697960S (ru)	2016-06-08
CN303641180S (ru)	2016-04-13
CN303536269S (ru)	2016-01-06
CN303536362S (ru)	2016-01-06
CN303634946S (ru)	2016-04-06
CN303712411S (ru)	2016-06-15
CN303634920S (ru)	2016-04-06